MedPath

Evaluation of the Effects of Oxygen Therapy and Enalapril for Diabetic Macular Ischemia

Phase 1
Conditions
Diabetic Macular Ischemia
Interventions
Drug: placebo
Other: oxygen
Registration Number
NCT00899587
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

In this study, patients were divided into 3 group with 35 cases including: 1.oxygen 2.enalapril 3.control.

In the beginning of the study, best corrected visual acuity (BCVA), uncorrected visual acuity (UCVA), and optical coherence tomography (OCT) were measured. Patients in the oxygen group were given oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month. In the enalapril group, patients were given enalapril 5 mg every night and placebo was given for the patients in third group. At the end of first month the patients' vision was checked again and at the the end of the third month the first physical examinations were performed. In the first group, arterial blood gas (ABG) was taken before and after oxygen therapy as well.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • Patients diagnosed with diabetic macular ischemia
Exclusion Criteria
  • HTN > 1140/90 or HTN controlled by ACE inhibitors
  • FBS > 200
  • Severe anemia, COPD, cataract, HRPDR and diffuse macular edema

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Controlplacebo-
Oxygenoxygen-
Enalaprilenalapril-
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ophthalmic Research Center

🇮🇷

Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath